Pfizer (NYSE: PFE) is expected to report Q3 earnings on Oct. 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pfizer's revenues will wither -14.6% and EPS will wither -16.1%.

The average estimate for revenue is $14.68 billion. On the bottom line, the average EPS estimate is $0.52.

Revenue details
 Last quarter, Pfizer recorded revenue of $15.06 billion. GAAP reported sales were 8.7% lower than the prior-year quarter's $16.49 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.62. GAAP EPS of $0.43 for Q2 were 30% higher than the prior-year quarter's $0.33 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 82.1%, 50 basis points better than the prior-year quarter. Operating margin was 36.4%, 470 basis points better than the prior-year quarter. Net margin was 21.6%, 580 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $59.55 billion. The average EPS estimate is $2.21.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 5,463 members out of 6,055 rating the stock outperform, and 592 members rating it underperform. Among 1,559 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 1,460 give Pfizer a green thumbs-up, and 99 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pfizer is outperform, with an average price target of $24.92.

Can your portfolio provide you with enough income to last through retirement? You'll need more than Pfizer. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.